Assessment of pro- and anti-inflammatory cytokine levels in two-phase surgical treatment of patients with advanced proliferative diabetic retinopathy
https://doi.org/10.21516/2072-0076-2021-14-3-14-18
Abstract
The purpose is to estimate the content of pro- and anti-inflammatory cytokines (IL-1 , IL-8, IL-10, MCP-1, ICAM-1, VEGF) in the tear liquid of patients with advanced proliferative diabetic retinopathy (PDR) and complicated primary cataract after phacoemulsification and IOL implantation performed simultaneously with vitreoretinal surgery vs. vitreoretinal surgery alone.
Material and methods. 34 patients with PDR and complicated primary cataract were divided into two groups. Group 1 received a two-phase surgical procedure: (a) vitreoretinal surgery (VRS) with silicone oil tamponade followed by (b) phacoemulsification surgery, IOL implantation and silicone oil removal. Group 2 was subjected to (a) phacoemulsification simultaneously with vitreoretinal surgery and silicone oil tamponade and (b) silicone oil removal from the vitreous cavity. Both groups had their tear liquid samples examined before the surgery and on the 2nd day after the 1stphase.
Results. Group 2 revealed a 2 to 2.5 times higher concentration of IL-8, MCP-1 and ICAM-1 as compared to Group 1.
Conclusion. Increased concentrations of IL-8, MCP-1, and ICAM-1 in the tear after phacoemulsification surgery and IOL implantation coupled with vitreoretinal surgery as compared to vitreoretinal surgery alone requires additional research of the role played by the inflammatory component in the pathogenesis of postsurgical complications in advanced PDR patients.
About the Authors
K. I. Konovalova
N.I. Pirogov National Medical and Surgical Center
Russian Federation
Russian Federation
ophthalmologist
70, Nizhnyaya Pervomayskaya St., Moscow, 105203, Russia
M. M. Shishkin
N.I. Pirogov National Medical and Surgical Center
Russian Federation
Russian Federation
Dr. of Med. Sci., professor, chief ophthalmologist
70, Nizhnyaya Pervomayskaya St., Moscow, 105203, Russia
R. R. Fayzrakhmanov
N.I. Pirogov National Medical and Surgical Center
Russian Federation
Russian Federation
Dr. of Med. Sci., head of the center of ophthalmology
70, Nizhnyaya Pervomayskaya St., Moscow, 105203, Russia
References
1. Petrachkov D.V., Kazakov I.S., Artemov M.A., Arzhukhanov D.D. Features of the postoperative period in patients with traction retinal detachment on the background of proliferative diabetic retinopathy with the completion of surgery on a balanced salt solution (without tamponade). Sovremennye tekhnologii v oftal’mologii. 2019; 26 (1): 147–52 (in Russian). https://doi.org/10.25276/2312-4911-2019-1-147-152
2. Rey A., Jurgens I., Maseras X., et al. Visual outcome and complications of cataract extraction after pars plana vitrectomy. Clinical Ophthalmology. 2018; 12: 989–94. https://doi.org/10.2147/opth.s161223
3. Rajesh S.J. Phacoemulsification in completely vitrectomized eyes: intraoperative analysis of modified phaco sleeve. Indian Journal of Ophthalmology. 2016; 64 (9): 659–62. https://doi.org/10.4103/0301-4738.97072
4. Konovalova K.I., Shishkin M.M., Fayzrakhmanov R.R. Phacoemulsification of primary cataract by the second stage after vitreoretinal surgery of PDR patients. Diabetes mellitus. 2020; 23 (5): 452–8 (in Russian). https://doi.org/10.14341/DM12256
5. Rivas-Aguino P., Garcia-Amaris R.A., Berrocal M.H., et al. Pars plana vitrectomy, phacoemulsification and intraocular lens implantation for the management of cataract and proliferative diabetic retinopathy: comparison of a combined versus two-step surgical approach. Arch. Soc. Esp. Oftalmol. 2009; 84 (1): 31–8. https://doi.org/10.4321/s0365-66912009000100005
6. Treumer F., Bunse A., Rudolf M., Roider J. Pars plana vitrectomy, phacoemulsification and intraocular lens implantation. Comparison of clinical complications in a combined versus two-step surgical approach. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2006; 244 (7): 808–15. https://doi.org/10.1007/s00417-005-0146-9
7. Trunov A.N., Chernykh D.V., Eremina A.V., Trunov V.V. Cytokines and growth factors in the pathogenesis of proliferative diabetic retinopathy. The Fyodorov Journal of Ophthalmic Surgery. 2017; 1: 93–7 (in Russian). https://doi.org/10.25276/0235-4160-2017-1-93-97
8. Neroev V.V., Zaytseva O.V., Balatskaya N.V., Lazutova A.A. Local and systemic production of 45 cytokines in complicated proliferative diabetic retinopathy. Medical Immunology. 2020; 22 (2): 301–10 (in Russian). https://doi.org/10.15789/1563-0625-LAS-1802
9. Lopez-Contreras A.K., Martinez-Ruiz M.G., Olvera-Montano C., et al. Importance of the use of oxidative stress biomarkers and inflammatory profile in aqueous and vitreous humor in diabetic retinopathy. Antioxidants (Basel). 2020. 9 (9): 891. https://doi.org/10.3390/antiox9090891
10. Raczynska D., Lisowska K.A., Pietruczuk K., et al. The level of cytokines in the vitreous body of severe proliferative diabetic retinopathy patients undergoing posterior vitrectomy. Current pharmaceutical design. 2018; 24 (27): 3276–81. https://doi.org/10.2174/1381612824666180926110704
11. Yoshida S., Kubo Y., Kobayashi Y., et al. Increased vitreous concentration of MCP-1 and IL-6 after vitrectomy in patients with proliferative diabetic retinopathy: possible association with postoperative macular oedema. British Journal of Ophthalmology. 2015; 99 (7): 960–6. http://dx.doi.org/10.1136/bjophthalmol-2014-306366
12. Balashevich L.I., Brzhesky V.V., Izmailov A.S. Ocular manifestations of diabetes mellitus. Izd. Dom SPb MAPO; 2004 (in Russian).
13. Wakabayashi Y., Usui Y., Okunuki Y., et al. Intraocular VEGF level as a risk factor for postoperative complications after vitrectomy for proliferative diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 2012; 53 (10): 6403–10. https://doi.org/10.1167/iovs.12-10367
14. Boss J.D., Singh P.K., Pandya H.K., et al. Assessment of neurotrophins and inflammatory mediators in vitreous of patients with diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 2017; 58: 5594–603. https://doi.org/10.1167/iovs.17-21973
15. Rubsam A., Parikh S., Fort P.E. Role of inflammation in diabetic retinopathy. International Journal of Molecular Sciences. 2018; 19 (4): 942. https://doi.org/10.3390/ijms19040942
16. Liu J., Shi B., He S., et al. Changes to tear cytokines of type 2 diabetic patients with or without retinopathy. Molecular Vision. 2010 Dec; 16: 2931-8. PMID: 21203348
17. Jonas J.B., Jonas R.A., Neumaier M., Findeisen P. Cytokine concentration in aqueous humor of eyes with diabetic macular edema. Retina. 2012; 32 (10): 2150–7. https://doi.org/10.1097/IAE.0b013e3182576d07
18. Ying Yan, Li Zhu, Ling Hong, et al. The impact of ranibizumab on the level of intercellular adgesion molecule type 1 in the vitreous of eyes with proliferative diabetic retinopathy. Acta Ophthalmologica. 2016; 94 (4): 358–64. https://doi.org/10.1111/aos.12806
19. Bhagat N., Grigorian R.A., Tutela A., Zarbin M.A. Diabetic macular edema: pathogenesis and treatment. Survey Ophthalmology. 2009; 54 (1): 1–32. https://doi.org/10.1016/j.survophthal.2008.10.001
20. Borzilova Yu.A., Boldyreva L.A., Shlyk I.V., et al. The level of VEGF-A in the lacrimal fluid of diabetic retinopathy. Kubanskii nauchnyi meditsinskii vestnik. 2015; 6 (155): 16–8 (in Russian).
Review
For citations:
Konovalova K.I., Shishkin M.M., Fayzrakhmanov R.R. Assessment of pro- and anti-inflammatory cytokine levels in two-phase surgical treatment of patients with advanced proliferative diabetic retinopathy. Russian Ophthalmological Journal. 2021;14(3):14-18. (In Russ.) https://doi.org/10.21516/2072-0076-2021-14-3-14-18
Views:
738
Email this article 